USA –
CAMBRIDGE, MA, Solarea Bio announced it has raised $11.2M in a Series A financing led by S2G Ventures.
Solarea Bio, a biotech company based in Cambridge, MA developing microbial-based solutions to aid human health, announced it has raised $11.2M in a Series A financing. The round was led by S2G Ventures and Bold Capital Partners, along with continued investment from Viking Global and additional investment from the Gisev Family Office as a syndicate investor.
Solarea Bio is a biotechnology company based in Cambridge, MA developing new microbiome-based solutions to some of the world's largest health problems. Solarea was founded in 2017 by a group of scientists and entrepreneurs eager to radically alter our understanding of the human microbiome and utilize its power to improve human health.
Solarea's breakthrough came from the combined efforts of the company's co-founders who established a link between the discovery of an untapped source of microorganisms with probiotic potential in healthy foods, and their applications in inflammatory processes including the gut-musculoskeletal axis.
Solarea Bio
